A Study To Investigate The Effect Of PD-217,014 On Abdominal Pain/Discomfort In Patients With IBS.

Pfizer

Status and phase: Completed; Phase 2

Conditions: Irritable Bowel Syndrome

Treatments: Drug: PD-217,014

Study type: Interventional

Funder types: Industry

Identifiers

NCT00139672

A4451007

Details and patient eligibility

About

The purpose of this study is to determine the effectiveness of PD-217,014 in the treatment of abdominal pain/discomfort associated with irritable bowel disease.

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males and females having Irritable bowel syndrome as defined by the Rome II criteria.
• Patients must have had normal examination of colon anatomy within the last 5 years

Exclusion criteria

• Patient with an organic gastrointestinal disease.
• Patients with poor renal function.
• Patients with severe constipation.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind